Akoustis Technologies, INC

Aktis Oncology reported Q1 2026 financial results, highlighting progress in its radiopharmaceutical pipeline with two key drug candidates, AKY-1189 and AKY-2519, advancing in clinical trials.

Aktis Oncology has appointed industry veteran Dr. Glenn Gormley to its Board of Directors and established a new Science and Technology Committee.

Akoustis Technologies, now ATech (Parent) Resolution Corp., finalizes the sale of substantially all assets to Tune Holdings, a SpaceX subsidiary, for $30.2 million following bankruptcy proceedings.

Akoustis Technologies will be delisted from the Nasdaq Capital Market due to failure to maintain a minimum bid price and its Chapter 11 bankruptcy filing.

Akoustis Technologies has filed for Chapter 11 bankruptcy to facilitate a strategic sale of its business and assets, aiming to ensure continued operations and a sale free of prior legal encumbrances.

Akoustis Technologies has adjourned its 2024 Annual Meeting of Stockholders due to a lack of quorum and rescheduled it for January 9, 2025.

Akoustis Technologies reported a net loss of $6.4 million for the quarter ended September 30, 2024, while facing significant financial and legal challenges.

Akoustis Technologies reports its Q3 2024 results, highlighting a slight revenue increase but significant net losses and ongoing financial and legal challenges.

Akoustis Technologies reported a net loss for the quarter ended December 31, 2023, despite increased revenue, as the company implements cost-saving measures and navigates ongoing financial challenges.

Clinical-stage radiopharma Aktis Oncology reported a $63.7M 2025 net loss, strengthened liquidity with a $335.3M January 2026 IPO and Lilly collaboration, and guided cash runway into 2029 as it advances Nectin-4 and B7-H3 programs.

Akoustis Technologies has filed an amendment to its annual report to include cybersecurity risk disclosures and updated certifications from its CEO and CFO.

Akoustis Technologies reports a challenging fiscal year marked by a significant legal loss, substantial operating losses, and doubts about its ability to continue as a going concern.

Director Glenn Gormley was granted 37,866 stock options in Aktis Oncology, Inc. with an exercise price of $18.09.

Akoustis Technologies has adjourned its 2024 Annual Meeting of Stockholders due to a lack of quorum and extended the voting period to January 8, 2025.

Akoustis Technologies has adjourned its 2024 Annual Meeting due to a lack of quorum and extended the voting period to allow more stockholders to participate.

Akoustis Technologies hires Kingsdale Shareholder Services to assist with proxy solicitation for the upcoming annual meeting on November 21, 2024.

Akoustis Technologies receives conditional approval for continued listing on The Nasdaq Capital Market, contingent on meeting minimum bid price and stockholders' equity requirements.

Akoustis Technologies has filed a definitive proxy statement with the SEC.

Akoustis Technologies is set to conduct its 2024 Annual Meeting of Stockholders virtually on November 21, 2024, including proposals for director elections, executive compensation, a reverse stock split, and auditor ratification.

Blue Owl Capital Holdings LP has filed a Schedule 13G, reporting beneficial ownership of 5.92% of Aktis Oncology, Inc. common stock as of March 31, 2026.